RxDoctor Payments Data

Paul Bretton, MD

Urology · Cape Coral, FLNPI 1649245036

Payments from drug & device makers

$1,373in general payments, 2019–2025

Across 41 payments — averaging $33.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$267
  • Johnson & Johnson$218
  • Teleflex LLC$173
  • Procept Biorobotics Corporation$129
  • Urogen Pharma, Inc.$120
  • Astellas Pharma US Inc$96
  • plus $370 from 11 others

What the payments were for

  • Food & beverage$1,35999%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,373 in reported general payments places this provider in the 25th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$187,069
Medicare patients
481
Services billed
4,919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide35$486,185
Abiraterone Acetate25$134,124
MyrbetriqMirabegron44$26,821
Tamsulosin Hcl433$6,015
Bicalutamide71$3,252
Solifenacin Succinate56$1,327
Finasteride114$1,268
Testosterone Cypionate17$1,070
Cephalexin349$1,054
Alfuzosin Hcl ErAlfuzosin Hcl36$944
Imipramine Hcl40$656
Ciprofloxacin Hcl84$593
Dutasteride12$570
NitrofurantoinNitrofurantoin Macrocrystal19$512
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim49$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$96$513,00779 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 935 urology providers in Florida.

Other urology in Cape Coral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →